ECSP014065A - Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero - Google Patents

Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero

Info

Publication number
ECSP014065A
ECSP014065A EC2001004065A ECSP014065A ECSP014065A EC SP014065 A ECSP014065 A EC SP014065A EC 2001004065 A EC2001004065 A EC 2001004065A EC SP014065 A ECSP014065 A EC SP014065A EC SP014065 A ECSP014065 A EC SP014065A
Authority
EC
Ecuador
Prior art keywords
cognitive dysfunction
pharmaceutically acceptable
disease
agonist
mammal
Prior art date
Application number
EC2001004065A
Other languages
English (en)
Inventor
Neill Brian Thomas O
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Steven Bradley Sands
Eric Jacob Watsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP014065A publication Critical patent/ECSP014065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica y un procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero, que comprende la administración de un agonista parcial del receptor de nicotina o una sal farmacéuticamente aceptable del mismo; y un inhibidor de acetilcolinesterasa, un inhibidor de butilcolinesterasas, un agente estrogénico, un modulador selectivo del receptor de estrógenos o un agonista muscarínico, o una sal farmacéuticamente aceptable de los mismos; y un vehículo farmacéuticamente aceptable. El agonista parcial del receptor de nicotina y el inhibidor de acetilcolinesterasa, el inhibidor de butilcolinesterasa, el estrógeno, el modulador selectivo del receptor de estrógenos o el agonista muscarínico están presente en cantidades que hacen a la composición eficaz en la potenciación de la cognición o en el tratamiento de enfermedades de disfunción cognitiva que incluyen, pero sin limitación, la Enfermedad de Alzheimer, deterioro cognitivo leve, disminución cognitiva relacionada con la edad, demencia vascular, demencia por enfermedad de Parkinson. Enfermedad de Huntington, Apoplejía, TBI, demencia asociada con el SIDA y esquizofrenia. También se describe el procedimiento de uso de estas composiciones.
EC2001004065A 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ECSP014065A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20279900P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
ECSP014065A true ECSP014065A (es) 2003-01-13

Family

ID=22751325

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004065A ECSP014065A (es) 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero

Country Status (17)

Country Link
US (2) US20010036949A1 (es)
EP (1) EP1280554A2 (es)
JP (1) JP2003532670A (es)
AR (1) AR028426A1 (es)
AU (1) AU2001248699A1 (es)
BR (1) BR0110487A (es)
CA (1) CA2409720A1 (es)
EC (1) ECSP014065A (es)
GT (1) GT200100075A (es)
MX (1) MXPA02011051A (es)
PA (1) PA8516701A1 (es)
PE (1) PE20011256A1 (es)
PY (1) PY0108909A (es)
SV (1) SV2002000440A (es)
TN (1) TNSN01068A1 (es)
UY (1) UY26693A1 (es)
WO (1) WO2001085145A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
EP2133078A1 (en) * 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
WO2002085843A2 (en) * 2001-04-20 2002-10-31 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
EA200400135A1 (ru) * 2001-08-31 2004-08-26 Ньюрочем ( Интернэшнл) Лимитед Применение производных амидинов для лечения амилоидоза
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
WO2005000806A2 (en) * 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
AU2005247948A1 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
EP2258358A3 (en) * 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) * 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
WO2008033299A2 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
JP2003532670A (ja) 2003-11-05
GT200100075A (es) 2001-12-31
US20010036949A1 (en) 2001-11-01
EP1280554A2 (en) 2003-02-05
UY26693A1 (es) 2001-12-28
US20030130303A1 (en) 2003-07-10
TNSN01068A1 (fr) 2005-11-10
AR028426A1 (es) 2003-05-07
BR0110487A (pt) 2003-04-01
AU2001248699A1 (en) 2001-11-20
PA8516701A1 (es) 2002-09-17
MXPA02011051A (es) 2003-03-10
WO2001085145A8 (en) 2001-12-13
WO2001085145A2 (en) 2001-11-15
PE20011256A1 (es) 2001-12-29
WO2001085145A3 (en) 2002-06-13
SV2002000440A (es) 2002-10-24
PY0108909A (es) 2003-11-03
CA2409720A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
ECSP014065A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero
DOP2002000345A (es) Uso de agonistas inversos de gaba en combinación con agonistas parciales del receptor de nicotina, estrógeno, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69017302D1 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
DE60124972D1 (de) Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung der weiblichen sexuellen Störungen
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
EA200201000A1 (ru) Гормон-заместительная терапия
ES2187575T3 (es) Hexapeptidos ciclicos dotados de actividad antibiotica.
BR0312232A (pt) Inibidores de caspases e seus usos
ATE370737T1 (de) Verwendung oraler formulierungen zur behandlung der weiblichen sexuellen störung
BR9509807A (pt) Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3
DE69130529D1 (de) Behandlung von erektionversagen
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
BR0104345A (pt) Tratamento combinado para a depressão e ansiedade
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
MX9207493A (es) Composicion farmaceutica que contiene compuestos de trioxolano y diperoxido.
AR004507A1 (es) Un profarmaco de trovafloxacina, un procedimiento para tratar una in infeccion bacteriana en un mamifero mediante el mismo, un procedimiento paraprepararlo y una composicion farmaceutica que lo comprende
DE60129846D1 (de) Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa